Gentulizumab, a novel anti-CD47 antibody with potent antitumor activity and demonstrates a favorable safety profile

MLA

Tao Wang, et al. “Gentulizumab, a Novel Anti-CD47 Antibody with Potent Antitumor Activity and Demonstrates a Favorable Safety Profile.” Journal of Translational Medicine, vol. 22, no. 1, Mar. 2024, pp. 1–13. EBSCOhost, https://doi.org/10.1186/s12967-023-04710-6.

APA

Tao Wang, Si-Qin Wang, Yin-Xiao Du, Dan-Dan Sun, Chang Liu, Shuang Liu, Ying-Ying Sun, Hai-Long Wang, Chun-Sheng Zhang, Hai-Long Liu, Lei Jin, & Xiao-Ping Chen. (2024). Gentulizumab, a novel anti-CD47 antibody with potent antitumor activity and demonstrates a favorable safety profile. Journal of Translational Medicine, 22(1), 1–13. https://doi.org/10.1186/s12967-023-04710-6

Chicago

Tao Wang, Si-Qin Wang, Yin-Xiao Du, Dan-Dan Sun, Chang Liu, Shuang Liu, Ying-Ying Sun, et al. 2024. “Gentulizumab, a Novel Anti-CD47 Antibody with Potent Antitumor Activity and Demonstrates a Favorable Safety Profile.” Journal of Translational Medicine 22 (1): 1–13. doi:10.1186/s12967-023-04710-6.